东北制药
(000597)
| 流通市值：72.57亿 | | | 总市值：73.50亿 |
| 流通股本：14.09亿 | | | 总股本：14.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,947,277,598.78 | 7,502,554,909.23 | 6,133,512,515.79 | 4,168,516,475.19 |
| 营业收入 | 1,947,277,598.78 | 7,502,554,909.23 | 6,133,512,515.79 | 4,168,516,475.19 |
| 二、营业总成本 | 1,828,004,577.99 | 6,888,697,612.66 | 5,783,158,351.88 | 3,882,658,259.57 |
| 营业成本 | 1,283,000,859.34 | 4,596,466,279.52 | 4,015,426,869.88 | 2,691,060,711.2 |
| 税金及附加 | 17,337,637.15 | 77,341,554.24 | 53,452,496.49 | 35,588,690.19 |
| 销售费用 | 307,273,222.11 | 1,381,892,380.61 | 1,047,384,162.17 | 723,176,074.76 |
| 管理费用 | 196,073,967.25 | 741,452,499.9 | 619,708,039.04 | 422,334,492.43 |
| 研发费用 | 31,999,540.39 | 117,763,982.51 | 53,424,342.8 | 35,982,806.73 |
| 财务费用 | -7,680,648.25 | -26,219,084.12 | -6,237,558.5 | -25,484,515.74 |
| 其中:利息费用 | 11,720,485.46 | 64,533,460.27 | 53,028,998.09 | 35,970,635.4 |
| 其中:利息收入 | 24,526,792.86 | 128,628,643.84 | 101,229,361.69 | 77,177,298.43 |
| 加:投资收益 | 1,350,929.69 | 5,160,420.26 | 3,443,648.35 | 2,933,210.38 |
| 资产处置收益 | 8,990.07 | 6,192,436.61 | 6,653.37 | 6,653.37 |
| 资产减值损失(新) | -64,439,253.74 | -125,566,328.87 | -81,626,706.85 | -66,265,579.63 |
| 信用减值损失(新) | -5,872,091.65 | 2,544,051.19 | -1,673,058.97 | -2,984,933.69 |
| 其他收益 | 25,452,646.61 | 75,573,520.7 | 65,858,411.31 | 58,754,908.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 75,774,241.77 | 577,761,396.46 | 336,363,111.12 | 278,302,474.34 |
| 加:营业外收入 | 1,812,944.94 | 48,519,028.2 | 15,948,218.26 | 3,826,875.39 |
| 减:营业外支出 | 11,510,920.82 | 32,370,037.1 | 3,273,589.14 | 3,370,647.46 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 66,076,265.89 | 593,910,387.56 | 349,037,740.24 | 278,758,702.27 |
| 减:所得税费用 | 30,704,850.96 | 170,628,065.67 | 128,984,177.81 | 111,863,983.59 |
| 六、净利润 | 35,371,414.93 | 423,282,321.89 | 220,053,562.43 | 166,894,718.68 |
| 持续经营净利润 | 35,371,414.93 | 423,282,321.89 | 220,053,562.43 | 166,894,718.68 |
| 归属于母公司股东的净利润 | 36,321,572.23 | 409,848,498.88 | 207,968,558.91 | 156,809,500.46 |
| 少数股东损益 | -950,157.3 | 13,433,823.01 | 12,085,003.52 | 10,085,218.22 |
| (一)基本每股收益 | 0.03 | 0.29 | 0.15 | 0.11 |
| (二)稀释每股收益 | 0.03 | 0.29 | 0.15 | 0.11 |
| 八、其他综合收益 | -58,468.97 | 629,692.33 | -451,414.36 | 238,720.64 |
| 归属于母公司股东的其他综合收益 | -58,741.05 | 632,527.83 | -453,406.95 | 239,912.99 |
| 九、综合收益总额 | 35,312,945.96 | 423,912,014.22 | 219,602,148.07 | 167,133,439.32 |
| 归属于母公司股东的综合收益总额 | 36,262,831.18 | 410,481,026.71 | 207,515,151.96 | 157,049,413.45 |
| 归属于少数股东的综合收益总额 | -949,885.22 | 13,430,987.51 | 12,086,996.11 | 10,084,025.87 |
| 公告日期 | 2025-04-29 | 2025-04-03 | 2024-10-24 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |